{"id":"https://openalex.org/W91038997","doi":"https://doi.org/10.4045/tidsskr.10.1126","title":"Naltrekson \u2013 h\u00f8ye forventninger til lave doser","display_name":"Naltrekson \u2013 h\u00f8ye forventninger til lave doser","alternate_titles":[],"publication_year":2011,"publication_date":"2011-05-06","ids":{"openalex":"https://openalex.org/W91038997","doi":"https://doi.org/10.4045/tidsskr.10.1126","mag":"91038997","pmid":"https://pubmed.ncbi.nlm.nih.gov/21556092"},"language":"no","primary_location":{"id":"doi:10.4045/tidsskr.10.1126","doi":"https://doi.org/10.4045/tidsskr.10.1126","is_oa":true,"landing_page_url":"https://doi.org/10.4045/tidsskr.10.1126","pdf_url":"https://tidsskriftet.no/sites/default/files/pdf2011--844-6.pdf","source":{"id":"https://openalex.org/S4210239295","display_name":"Tidsskrift for Den norske legeforening","issn_l":"0029-2001","issn":["0029-2001","0807-7096"],"is_oa":true,"is_in_doaj":true,"is_core":false,"listed_in":["ddh","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-20","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310314069","host_organization_name":"Norwegian Medical Association","host_organization_lineage":["https://openalex.org/P4310314069"],"host_organization_lineage_names":["Norwegian Medical Association"],"type":"journal"},"license":"cc-by-nd","license_id":"https://openalex.org/licenses/cc-by-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Tidsskrift for Den norske legeforening","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W91038997"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://tidsskriftet.no/sites/default/files/pdf2011--844-6.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063303274","display_name":"Guttorm Raknes","orcid":"https://orcid.org/0000-0002-3376-6761","observed_orcids":["https://orcid.org/0000-0002-3376-6761"]},"institutions":[{"id":"https://openalex.org/I4387152267","display_name":"Institute for Translational Research in Inflammation","ror":"https://ror.org/03qy9z186","country_code":"FR","type":"facility","lineage":["https://openalex.org/I154526488","https://openalex.org/I2279609970","https://openalex.org/I3018718406","https://openalex.org/I4387152267"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Guttorm Raknes","raw_affiliation_strings":["Steigen legesenter, 8283 Leinesfjord, Norway. guttorm.raknes@gmail.com","Steigen legesenter, 8283 Leinesfjord, Norway"],"raw_orcid":"https://orcid.org/0000-0002-3376-6761","affiliations":[{"raw_affiliation_string":"Steigen legesenter, 8283 Leinesfjord, Norway. guttorm.raknes@gmail.com","institution_ids":[]},{"raw_affiliation_string":"Steigen legesenter, 8283 Leinesfjord, Norway","institution_ids":["https://openalex.org/I4387152267"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5040575897","display_name":"Trude Giverhaug","orcid":"https://orcid.org/0000-0001-6699-857X","observed_orcids":["https://orcid.org/0000-0001-6699-857X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Trude Giverhaug","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.2275,"has_fulltext":true,"cited_by_count":5,"citation_normalized_percentile":{"value":0.46821723,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"131","issue":"8","first_page":"844","last_page":"844"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10814","display_name":"Neuropeptides and Animal Physiology","score":0.336899995803833,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10814","display_name":"Neuropeptides and Animal Physiology","score":0.336899995803833,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11199","display_name":"Pain Management and Opioid Use","score":0.328900009393692,"subfield":{"id":"https://openalex.org/subfields/2703","display_name":"Anesthesiology and Pain Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":0.03750000149011612,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/naltrexone","display_name":"naltrexone","score":0.996999979019165},{"id":"https://openalex.org/keywords/opioid-antagonists","display_name":"opioid antagonists","score":0.9480000138282776},{"id":"https://openalex.org/keywords/low-dose-naltrexone","display_name":"low-dose naltrexone","score":0.8339999914169312},{"id":"https://openalex.org/keywords/multiple-sclerosis","display_name":"multiple sclerosis","score":0.878000020980835},{"id":"https://openalex.org/keywords/crohn-s-disease","display_name":"Crohn's disease","score":0.996999979019165},{"id":"https://openalex.org/keywords/cancer","display_name":"cancer","score":0.6159999966621399},{"id":"https://openalex.org/keywords/autoimmune-disease","display_name":"autoimmune disease","score":0.972000002861023},{"id":"https://openalex.org/keywords/hiv-infection","display_name":"HIV infection","score":0.7950000166893005},{"id":"https://openalex.org/keywords/treatment-guidelines","display_name":"treatment guidelines","score":0.4869999885559082},{"id":"https://openalex.org/keywords/economic-savings","display_name":"economic savings","score":0.6470000147819519}],"concepts":[{"id":"https://openalex.org/C15708023","wikidata":"https://www.wikidata.org/wiki/Q80083","display_name":"Humanities","level":1,"score":0.4196302890777588},{"id":"https://openalex.org/C142362112","wikidata":"https://www.wikidata.org/wiki/Q735","display_name":"Art","level":0,"score":0.35077184438705444}],"mesh":[{"descriptor_ui":"D003424","descriptor_name":"Crohn Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009103","descriptor_name":"Multiple Sclerosis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009271","descriptor_name":"Naltrexone","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D009271","descriptor_name":"Naltrexone","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D009271","descriptor_name":"Naltrexone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D009292","descriptor_name":"Narcotic Antagonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D009292","descriptor_name":"Narcotic Antagonists","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D009292","descriptor_name":"Narcotic Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.4045/tidsskr.10.1126","doi":"https://doi.org/10.4045/tidsskr.10.1126","is_oa":true,"landing_page_url":"https://doi.org/10.4045/tidsskr.10.1126","pdf_url":"https://tidsskriftet.no/sites/default/files/pdf2011--844-6.pdf","source":{"id":"https://openalex.org/S4210239295","display_name":"Tidsskrift for Den norske legeforening","issn_l":"0029-2001","issn":["0029-2001","0807-7096"],"is_oa":true,"is_in_doaj":true,"is_core":false,"listed_in":["ddh","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-20","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310314069","host_organization_name":"Norwegian Medical Association","host_organization_lineage":["https://openalex.org/P4310314069"],"host_organization_lineage_names":["Norwegian Medical Association"],"type":"journal"},"license":"cc-by-nd","license_id":"https://openalex.org/licenses/cc-by-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Tidsskrift for Den norske legeforening","raw_type":"journal-article"},{"id":"pmid:21556092","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21556092","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.4045/tidsskr.10.1126","doi":"https://doi.org/10.4045/tidsskr.10.1126","is_oa":true,"landing_page_url":"https://doi.org/10.4045/tidsskr.10.1126","pdf_url":"https://tidsskriftet.no/sites/default/files/pdf2011--844-6.pdf","source":{"id":"https://openalex.org/S4210239295","display_name":"Tidsskrift for Den norske legeforening","issn_l":"0029-2001","issn":["0029-2001","0807-7096"],"is_oa":true,"is_in_doaj":true,"is_core":false,"listed_in":["ddh","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-20","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310314069","host_organization_name":"Norwegian Medical Association","host_organization_lineage":["https://openalex.org/P4310314069"],"host_organization_lineage_names":["Norwegian Medical Association"],"type":"journal"},"license":"cc-by-nd","license_id":"https://openalex.org/licenses/cc-by-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Tidsskrift for Den norske legeforening","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W91038997.pdf","grobid_xml":"https://content.openalex.org/works/W91038997.grobid-xml"},"referenced_works_count":9,"referenced_works":["https://openalex.org/W2005162573","https://openalex.org/W2030520122","https://openalex.org/W2032934212","https://openalex.org/W2045406685","https://openalex.org/W2116093385","https://openalex.org/W2126241051","https://openalex.org/W2132854289","https://openalex.org/W2171795872","https://openalex.org/W2462955967"],"related_works":["https://openalex.org/W4417233625","https://openalex.org/W3114891642","https://openalex.org/W3003506075","https://openalex.org/W3092384929","https://openalex.org/W6996265655","https://openalex.org/W3094076243","https://openalex.org/W4312680022","https://openalex.org/W4406094624","https://openalex.org/W2138380096","https://openalex.org/W2542168409"],"abstract_inverted_index":{"KronikkNaltrekson":[0],"-h\u00f8ye":[1],"forventninger":[2],"til":[3],"lave":[4,19],"doser8":[5],"Opioidantagonisten":[6],"naltrekson":[7],"hevdes":[8],"\u00e5":[9,44],"hjelpe":[10],"mot":[11],"b\u00e5de":[12],"kreft,":[13],"autoimmune":[14],"sykdommer":[15],"og":[16,27],"hivinfeksjon":[17],"i":[18],"doser.Selv":[20],"om":[21],"enkelte":[22],"studier":[23],"p\u00e5":[24,31],"multippel":[25],"sklerose":[26],"Crohns":[28],"sykdom":[29],"tyder":[30],"at":[32,54],"en":[33],"viss":[34],"effekt":[35,57],"ikke":[36,41],"kan":[37,69],"utelukkes,":[38],"gir":[39],"forskningen":[40],"grunnlag":[42],"for":[43],"anbefale":[45],"slik":[46],"behandling":[47],"ved":[48,58],"noen":[49,59],"sykdommer.Hvis":[50],"det":[51,64],"viser":[52],"seg":[53],"midlet":[55],"har":[56],"av":[60],"disse":[61],"tilstandene,":[62],"vil":[63],"v\u00e6re":[65],"et":[66],"behandlingsalternativ":[67],"som":[68],"gi":[70],"betydelige":[71],"\u00f8konomiske":[72],"innsparinger.":[73]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W91038997","counts_by_year":[{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":2}],"updated_date":"2026-11-14T11:04:58.165337","created_date":"2016-06-24T00:00:00"}
